Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial
Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial. // The Lancet Rheumatology. – URL: https://www.sciencedirect.com/science/article/pii/S2665991326002183?dgcid=rss_sd_all
Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial. The Lancet Rheumatology. https://www.sciencedirect.com/science/article/pii/S2665991326002183?dgcid=rss_sd_all
“Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial.” The Lancet Rheumatology.
@article{article69289,
title = {Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial},
journal = {The Lancet Rheumatology},
url = {https://www.sciencedirect.com/science/article/pii/S2665991326002183?dgcid=rss_sd_all}
}